Abstract
Protein kinases are key components of cell signalling pathways. Defects in these processes lead to diseases such as cancer, diabetes and arthritis and hence protein kinases have become targets for drug design and therapy. We recently reviewed progress in this field with reference to kinase inhibitors that are in clinical trials or in the clinic and for which structural information is available [1]. In this talk I shall review some of our work with reference to cell cycle protein kinases [2] and I shall expand the discussion to consider wider aspects of substrate recognition with reference to CDK2/cyclin A, CDK2/cyclin E [3], CDK7 [4] and polo-like kinase [5].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Acta Crystallographica Section A Foundations of Crystallography
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
